280 related articles for article (PubMed ID: 17181154)
1. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
[TBL] [Abstract][Full Text] [Related]
2. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
[TBL] [Abstract][Full Text] [Related]
3. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
5. Combined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain.
Tomaselli S; Meli M; Plescia J; Zetta L; Altieri DC; Colombo G; Ragona L
Chem Biol Drug Des; 2010 Nov; 76(5):382-91. PubMed ID: 20925690
[TBL] [Abstract][Full Text] [Related]
6. Rational design of shepherdin, a novel anticancer agent.
Plescia J; Salz W; Xia F; Pennati M; Zaffaroni N; Daidone MG; Meli M; Dohi T; Fortugno P; Nefedova Y; Gabrilovich DI; Colombo G; Altieri DC
Cancer Cell; 2005 May; 7(5):457-68. PubMed ID: 15894266
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
9. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CYP2E1 induces HepG2 cells death by the AMP kinase activator 5'-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
Zhuge J
Cell Biol Toxicol; 2009 Jun; 25(3):253-63. PubMed ID: 18473182
[TBL] [Abstract][Full Text] [Related]
11. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
Moser C; Lang SA; Stoeltzing O
Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
[TBL] [Abstract][Full Text] [Related]
12. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
13. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
[TBL] [Abstract][Full Text] [Related]
14. Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox.
Okada M; Itoh H; Hatakeyama T; Tokumitsu H; Kobayashi R
Biochem J; 2003 Sep; 374(Pt 2):433-41. PubMed ID: 12803546
[TBL] [Abstract][Full Text] [Related]
15. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
16. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
[TBL] [Abstract][Full Text] [Related]
17. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
18. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.
Xu W; Neckers L
Clin Cancer Res; 2007 Mar; 13(6):1625-9. PubMed ID: 17363512
[No Abstract] [Full Text] [Related]
19. Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect.
Orosz A; Szabo A; Szeman G; Janaky T; Somlai C; Penke B; Bodor A; Perczel A
Int J Biochem Cell Biol; 2006; 38(8):1352-62. PubMed ID: 16540363
[TBL] [Abstract][Full Text] [Related]
20. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.
Musso L; Dallavalle S; Merlini L; Bava A; Nasini G; Penco S; Giannini G; Giommarelli C; De Cesare A; Zuco V; Vesci L; Pisano C; Castorina M; Milazzo F; Cervoni ML; Dal Piaz F; De Tommasi N; Zunino F
Bioorg Med Chem; 2010 Aug; 18(16):6031-43. PubMed ID: 20655237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]